Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Free CEA binding substance in cancer sera.

A Bartorelli

    Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
    |January 1, 1987
    PubMed
    Summary

    Researchers discovered a novel "CEA Binding Substance" (CBS) in cancer patients with negative CEA tests. This substance specifically targets tumor cells, offering potential for improved cancer diagnostics.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Biological components in a standardized derivative of bovine colostrum.

    Journal of dairy science·2013
    Same author

    Percutaneous closure of iatrogenic atrial septal defect due to implantation of a left-left "Tandem Heart" ventricle assistance device in a postcardiotomy cardiac failure: six-year follow-up.

    The Journal of cardiovascular surgery·2012
    Same author

    Antibody-dependent cytotoxic activity on human cancer cells expressing UK 114 tumor membrane antigen.

    International journal of oncology·2011
    Same author

    Cytolytic and tumor inhibitory antibodies against UK114 protein in the sera of cancer patients.

    International journal of oncology·2011
    Same author

    Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting.

    International journal of cardiovascular interventions·2003
    Same author

    Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: The SOPHOS study.

    International journal of cardiovascular interventions·2002

    Area of Science:

    • Oncology
    • Immunology
    • Biochemistry

    Background:

    • Carcinoembryonic antigen (CEA) is a tumor marker often used in cancer diagnostics.
    • Limitations exist in current diagnostic markers, necessitating the search for novel biomarkers.
    • Understanding tumor-specific substances in patient serum can aid in early detection and diagnosis.

    Purpose of the Study:

    • To identify and characterize novel substances in cancer patient serum that may serve as diagnostic markers.
    • To investigate the presence and specificity of a newly found substance, termed "CEA Binding Substance" (CBS).
    • To evaluate the potential of CBS as a tumor-specific marker in adenocarcinoma.

    Main Methods:

    • Radioimmunoassay was employed to detect the presence of CBS in patient serum.
    • Immunocytochemical studies using adenocarcinoma and normal tissue sections were performed.
    • The ABC peroxidase method was utilized to visualize CBS binding to tissues.

    Main Results:

    • A substance, designated "CEA Binding Substance" (CBS), was identified in the serum of some cancer patients.
    • CBS was detected exclusively in patients with negative CEA test results.
    • Immunocytochemical analysis confirmed CBS binding specifically to tumoral tissue, demonstrating high tumor specificity and intense staining on tumor cells.

    Conclusions:

    • CBS represents a novel serum substance found in cancer patients, particularly those with negative CEA results.
    • The tumor-specific binding of CBS suggests its potential as a diagnostic marker for adenocarcinoma.
    • Further research into CBS could lead to improved immunodiagnostic strategies for cancer detection.

    Related Experiment Videos